The GRAS acceptance follows on heels of recent FDA acknowledgement of a new dietary ingredient (NDI) notification for Superba krill oil.
FDA has accepted, with no objections, a self-affirmed Generally Recognized as Safe (GRAS) notification for Aker BioMarine’s (Oslo, Norway) Superba krill oil. As such, Superba krill oil is now deemed safe for use in food and beverage.
The GRAS acceptance follows on heels of recent FDA acknowledgement of a new dietary ingredient (NDI) notification for Superba krill oil.
Matts Johansen, the company’s executive vice president of sales and marketing, stated, “…Aker BioMarine Antarctic has developed an extensive safety dossier for Superba krill oil. The FDA’s earlier acknowledgement of our NDI notification was important for our existing and future customers to introduce Superba products in all supplement channels, while the new self-affirmed GRAS notice acceptance solidly opens the door to applications in the food and beverage industries as well.”
The phospholipid-bound eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in Superba krill oil are said to be highly bioavailable. The company says it is now actively exploring functional food applications in the United States.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.